Related Experiment Video
Updated: Feb 24, 2026

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
Published on: February 23, 2024
[The breakthrough of personalized medicine, new hopes and new challenges]
Ronan Flippot1, Christophe Massard2, Edouard Auclin3
1Gustave-Roussy, département de médecine oncologique, 94800 Villejuif, France.
Abstract:
The development of personalized medicine in oncology is based on biomarkers that help select populations for more efficient and less toxic therapies. The onset of molecular biology led to new paradigms in drug development, with efficacy data reported in early clinical trials and accelerated approvals. Multiple clinical trials, including SHIVA, SAFIR-01 and MOSCATO-01, have been developed to evaluate the interest of treatment decision-making based on tumor molecular profiling, with the ambition to replace historical clinical and pathological classifications. Targeted molecular therapies have also drastically enhanced the prognosis of patients in several cancer subtypes, with increased use in the context of advanced palliative care. Breaking through those boundaries might lead to a true precision medicine in oncology, which implementation in clinical routine is now expected by patients and physicians.
Insights
Personalized medicine in oncology uses biomarkers for targeted therapies. Tumor molecular profiling in trials like SHIVA aims to improve cancer treatment decisions and patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Personalized medicine in oncology relies on biomarkers to guide efficient and less toxic therapies.
- Molecular biology advancements have transformed oncology drug development, enabling early efficacy reporting and accelerated approvals.
Purpose of the Study:
- To evaluate the utility of treatment decisions based on tumor molecular profiling.
- To explore the potential of precision medicine to replace traditional cancer classifications.
- To highlight the impact of targeted therapies on patient prognosis in advanced cancer care.
Main Methods:
- Analysis of data from clinical trials such as SHIVA, SAFIR-01, and MOSCATO-01.
- Utilizing tumor molecular profiling for treatment selection.
- Assessing efficacy and toxicity of targeted therapies.
Main Results:
- Tumor molecular profiling shows promise in guiding treatment decisions.
- Targeted therapies have significantly improved outcomes for specific cancer subtypes.
- Increased application of targeted therapies in palliative care settings.
Conclusions:
- Implementing precision medicine in routine oncology care is increasingly expected by patients and physicians.
- Molecular profiling represents a paradigm shift in cancer treatment strategy.
- Further integration of precision oncology aims to enhance patient care and outcomes.
More Related Videos
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics and Pharmacogenomics: Overview
Microorganisms in Medicine and Therapeutics
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer